Tvardi Therapeutics, Inc. Share Price

Tvardi Therapeutics, Inc. Share Price

TVRD
$0.00
+0.00 (0.00%)
  • Performance
  • Chart
  • About
  • Price history
  • FAQs

Tvardi Therapeutics, Inc. Stock Performance

Open
N/A
Prev. Close
N/A
Circuit Range
N/A
Day Range
N/A
Year Range
N/A
Volume
N/A
Average Traded
N/A

Tvardi Therapeutics, Inc. Share Price Chart

$0.00
Please wait...

About Tvardi Therapeutics, Inc.

Tvardi Therapeutics, Inc. operates as a biotechnology company that develops medicines for cancer, chronic inflammation diseases, and fibrosis diseases. It develops inhibitors of STAT3, a molecule implicated in the initiation and progression of cancer and fibrosis. Its pipeline includes TTI-101, a small-molecule inhibitor of signal transducers and activators of transcription; and TTI-109, a STAT3 inhibitor for clinical use, including tolerability, bioavailability, and potency. Tvardi Therapeutics, Inc. was incorporated in 2017 and is based in Sugar Land, Texas.

Tvardi Therapeutics, Inc. Historical Data

DayOpenCloseChange %

FAQs on Tvardi Therapeutics, Inc. Share Price

Can I buy Tvardi Therapeutics, Inc. shares in India?

chevron-up
Yes. You can buy Tvardi Therapeutics, Inc. in India by opening an international trading account.

What is the share price of Tvardi Therapeutics, Inc.?

chevron-up
As on 07 Feb '26, the share price of Tvardi Therapeutics, Inc. TVRD is $0.00. If you are investing from India, it is a good idea to check the current exchange rate and calculate the value in rupees before making your investment.

What is the 5 year returns of Tvardi Therapeutics, Inc.?

chevron-up
The 5 year returns of Tvardi Therapeutics, Inc. is as on 07 Feb '26.

What are the high & low stock price of Tvardi Therapeutics, Inc. today?

chevron-up
Tvardi Therapeutics, Inc. stock price hit a high of $0.00 and low of $0.00 as on 07 Feb '26.

What is the 52-week high and low of Tvardi Therapeutics, Inc. stock?

chevron-up
The 52-week high of Tvardi Therapeutics, Inc. stock is $0.00, while the 52-week low is $0.00 as on 07 Feb '26.